Developer docs
API playgroundTry for free, no card

Search company profiles

PharmaCyte Biotech

Full company profile

uuid0003ejn

Namestring
PharmaCyte Biotech
Legal namestring
PharmaCyte Biotech, Inc.
Company typeenum
Private
Founded yearint
1996
Descriptiontext

PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company headquartered in Las Vegas, Nevada (corporate address 3960 Howard Hughes Parkway, Suite 500) and listed on Nasdaq under ticker PMCB. Founded in 1996, the company employs between 1 and 10 people and is focused on developing cellular therapies for cancer and diabetes using its proprietary Cell-in-a-Box technology platform, which encapsulates and delivers therapeutic cells.

The Cell-in-a-Box platform is the company's single core product asset and underpins all clinical development programs. PharmaCyte is pursuing indications including malignant ascites (a complication of advanced-stage cancers) and diabetes, with the encapsulation architecture positioned as a novel delivery method for targeted cellular therapies. No commercialized products exist, and pricing is therefore not applicable; the company operates in clinical development and prepares for eventual FDA approval pathways rather than direct product sales.

The business model is pre-revenue and dependent on equity capital markets. The company has raised capital through public offerings (notably a $15M offering in August 2021 led by H.C. Wainwright raising ~$13.6M net, and a $7M raise in August 2025 led by existing investors). In 2022, the company underwent governance changes following a cooperation agreement with Iroquois Capital that installed five new independent directors and established a Business Review Committee to evaluate strategic alternatives for shareholder value. Patient and provider engagement is limited to clinical trials rather than commercial distribution.

Short descriptiontext

PharmaCyte Biotech is a clinical-stage public biotechnology company developing cellular therapies for cancer and diabetes using its proprietary Cell-in-a-Box encapsulation platform, with no commercialized products and revenue dependent on future FDA approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLas Vegas, United States
HQ citystring
Las Vegas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cellular therapy development, cancer treatment research, cell encapsulation technology, biotechnology pharmaceuticals, diabetes treatment research
Industry2 codes
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biotechnology Cellular Therapy
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PharmaCyte Biotech is a clinical-stage biotechnology company developing cellular therapies for cancer (notably advanced-stage malignancies with malignant ascites) and diabetes using its proprietary Cell-in-a-Box encapsulation platform. The technology encapsulates therapeutic cells in a cellulose-based matrix to enable targeted delivery of biologically active treatments. The company has no commercially approved products and is focused on advancing its pipeline through clinical development and regulatory pathways.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

PharmaCyte Biotech is a clinical-stage biotechnology company developing a single unified product platform: the Cell-in-a-Box technology. This core technology platform is designed to encapsulate and deliver therapeutic cells for the treatment of cancer and diabetes. The company's product pipeline centers on leveraging this cellular delivery system to create novel therapeutic approaches for malignant ascites (a complication of advanced-stage cancers) and diabetes treatment. The Cell-in-a-Box platform serves as the foundational technology underpinning all of PharmaCyte's clinical development programs.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for advanced cancers; the most direct comparable to PharmaCyte's cell-therapy approach in oncology, with a similar focus on hard-to-treat advanced-stage solid tumors.

TypeDirect peer
Description

Clinical-stage cell therapy company developing engineered T-cell therapies for solid tumors; directly comparable to PharmaCyte as a small-cap, clinical-stage cell therapy company targeting oncology indications.

TypeDirect peer
Description

Clinical-stage cell therapy company with a platform approach to develop off-the-shelf NK and T-cell cancer therapies; comparable to PharmaCyte as a platform-based cell therapy developer targeting multiple oncology indications.

4bluebird bio
TypeDirect peer
Description

Clinical-stage gene and cell therapy company with multiple programs in oncology and rare diseases; directly comparable as a small-cap, clinical-stage developer of cellular therapies, though now focused on gene therapy.

TypeDirect peer
Description

Clinical-stage allogeneic CAR T-cell therapy company for cancer; directly comparable to PharmaCyte as a clinical-stage cell therapy developer focused on oncology with a platform-based approach.

TypeDirect peer
Description

Clinical-stage gene and cell therapy company developing allogeneic CAR T-cell therapies for cancer; directly comparable as a clinical-stage cell therapy platform company in oncology.

7ViaCyte
TypeDirect peer
Description

Clinical-stage cell therapy company developing encapsulated stem cell-derived therapies for diabetes; the most direct peer to PharmaCyte's diabetes program, sharing the encapsulated cell-therapy approach.

8Sigilon Therapeutics
TypeEmerging player
Description

Clinical-stage cell therapy company developing encapsulated cell therapies for chronic diseases including diabetes; closely comparable to PharmaCyte's Cell-in-a-Box encapsulation concept in diabetes and adjacent applications.

TypeEmerging player
Description

Clinical-stage cell therapy company developing engineered NK cell therapies for cancer; comparable to PharmaCyte as a small-cap clinical-stage cell therapy developer focused on oncology applications.

TypeEmerging player
Description

Clinical-stage cell therapy company developing autologous and allogeneic T-cell therapies for solid tumors; comparable to PharmaCyte as a clinical-stage cell therapy developer targeting oncology indications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PharmaCyte Biotech

Biotechnology Cellular Therapypharmacytebiotech.com

PharmaCyte Biotech is a clinical-stage public biotechnology company developing cellular therapies for cancer and diabetes using its proprietary Cell-in-a-Box encapsulation platform, with no commercialized products and revenue dependent on future FDA approval.

What PharmaCyte Biotech does

PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company headquartered in Las Vegas, Nevada (corporate address 3960 Howard Hughes Parkway, Suite 500) and listed on Nasdaq under ticker PMCB. Founded in 1996, the company employs between 1 and 10 people and is focused on developing cellular therapies for cancer and diabetes using its proprietary Cell-in-a-Box technology platform, which encapsulates and delivers therapeutic cells.

The Cell-in-a-Box platform is the company's single core product asset and underpins all clinical development programs. PharmaCyte is pursuing indications including malignant ascites (a complication of advanced-stage cancers) and diabetes, with the encapsulation architecture positioned as a novel delivery method for targeted cellular therapies. No commercialized products exist, and pricing is therefore not applicable; the company operates in clinical development and prepares for eventual FDA approval pathways rather than direct product sales.

The business model is pre-revenue and dependent on equity capital markets. The company has raised capital through public offerings (notably a $15M offering in August 2021 led by H.C. Wainwright raising ~$13.6M net, and a $7M raise in August 2025 led by existing investors). In 2022, the company underwent governance changes following a cooperation agreement with Iroquois Capital that installed five new independent directors and established a Business Review Committee to evaluate strategic alternatives for shareholder value. Patient and provider engagement is limited to clinical trials rather than commercial distribution.

PharmaCyte Biotech firmographics

Firmographics
Name
PharmaCyte Biotech
Legal name
PharmaCyte Biotech, Inc.
Website
https://pharmacytebiotech.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
1–10 employees
Short description
PharmaCyte Biotech is a clinical-stage public biotechnology company developing cellular therapies for cancer and diabetes using its proprietary Cell-in-a-Box encapsulation platform, with no commercialized products and revenue dependent on future FDA approval.
Ownership category
akta.pro rank

PharmaCyte Biotech industry classification

Industry
Product category
Biotechnology Cellular Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Keywords

  • Cellular therapy development
  • Cancer treatment research
  • Cell encapsulation technology
  • Biotechnology pharmaceuticals
  • Diabetes treatment research

Where PharmaCyte Biotech is headquartered

Location

Headquarters

HQ city
Las Vegas
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PharmaCyte Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Marketing channels5 records

PharmaCyte Biotech product offering

Product offering

Core offering

PharmaCyte Biotech is a clinical-stage biotechnology company developing cellular therapies for cancer (notably advanced-stage malignancies with malignant ascites) and diabetes using its proprietary Cell-in-a-Box encapsulation platform. The technology encapsulates therapeutic cells in a cellulose-based matrix to enable targeted delivery of biologically active treatments. The company has no commercially approved products and is focused on advancing its pipeline through clinical development and regulatory pathways.

Product overview

PharmaCyte Biotech is a clinical-stage biotechnology company developing a single unified product platform: the Cell-in-a-Box technology. This core technology platform is designed to encapsulate and deliver therapeutic cells for the treatment of cancer and diabetes. The company's product pipeline centers on leveraging this cellular delivery system to create novel therapeutic approaches for malignant ascites (a complication of advanced-stage cancers) and diabetes treatment. The Cell-in-a-Box platform serves as the foundational technology underpinning all of PharmaCyte's clinical development programs.

Differentiator

Problem solved

Functional benefit

Companies that use PharmaCyte Biotech

Customer profile

Segments1 record

Ideal customer profiles2 records

PharmaCyte Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

PharmaCyte Biotech partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

PharmaCyte Biotech competitors and assessment

Company assessment

Direct peers

  • Iovance Biotherapeutics: Clinical-stage cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for advanced cancers; the most direct comparable to PharmaCyte's cell-therapy approach in oncology, with a similar focus on hard-to-treat advanced-stage solid tumors.
  • Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered T-cell therapies for solid tumors; directly comparable to PharmaCyte as a small-cap, clinical-stage cell therapy company targeting oncology indications.
  • Fate Therapeutics: Clinical-stage cell therapy company with a platform approach to develop off-the-shelf NK and T-cell cancer therapies; comparable to PharmaCyte as a platform-based cell therapy developer targeting multiple oncology indications.
  • bluebird bio: Clinical-stage gene and cell therapy company with multiple programs in oncology and rare diseases; directly comparable as a small-cap, clinical-stage developer of cellular therapies, though now focused on gene therapy.
  • Allogene Therapeutics: Clinical-stage allogeneic CAR T-cell therapy company for cancer; directly comparable to PharmaCyte as a clinical-stage cell therapy developer focused on oncology with a platform-based approach.
  • Cellectis: Clinical-stage gene and cell therapy company developing allogeneic CAR T-cell therapies for cancer; directly comparable as a clinical-stage cell therapy platform company in oncology.
  • ViaCyte: Clinical-stage cell therapy company developing encapsulated stem cell-derived therapies for diabetes; the most direct peer to PharmaCyte's diabetes program, sharing the encapsulated cell-therapy approach.

Emerging players

  • Sigilon Therapeutics: Clinical-stage cell therapy company developing encapsulated cell therapies for chronic diseases including diabetes; closely comparable to PharmaCyte's Cell-in-a-Box encapsulation concept in diabetes and adjacent applications.
  • Nkarta: Clinical-stage cell therapy company developing engineered NK cell therapies for cancer; comparable to PharmaCyte as a small-cap clinical-stage cell therapy developer focused on oncology applications.
  • Tessa Therapeutics: Clinical-stage cell therapy company developing autologous and allogeneic T-cell therapies for solid tumors; comparable to PharmaCyte as a clinical-stage cell therapy developer targeting oncology indications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

PharmaCyte Biotech social profiles

Digital presence

PharmaCyte Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PharmaCyte Biotech leadership team

Management profile

Number of profiles

Profiles5 records

PharmaCyte Biotech funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PharmaCyte Biotech M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmaCyte Biotech

What does PharmaCyte Biotech do?

PharmaCyte Biotech is a clinical-stage biotechnology company developing cellular therapies for cancer (notably advanced-stage malignancies with malignant ascites) and diabetes using its proprietary Cell-in-a-Box encapsulation platform. The technology encapsulates therapeutic cells in a cellulose-based matrix to enable targeted delivery of biologically active treatments. The company has no commercially approved products and is focused on advancing its pipeline through clinical development and regulatory pathways.

Is PharmaCyte Biotech a public or private company?

PharmaCyte Biotech is a private company. It is classified as public and is currently operating.

When was PharmaCyte Biotech founded?

PharmaCyte Biotech was founded in 1996. It employs 1 to 10 people.

Where is PharmaCyte Biotech based?

PharmaCyte Biotech is headquartered in Las Vegas, United States, in the North America region.

Who are PharmaCyte Biotech's main competitors?

Direct peers on record are Iovance Biotherapeutics, Adaptimmune Therapeutics, Fate Therapeutics, bluebird bio, Allogene Therapeutics, Cellectis and ViaCyte. Emerging players are Sigilon Therapeutics, Nkarta and Tessa Therapeutics.

Does PharmaCyte Biotech have an API?

No public API is recorded for PharmaCyte Biotech.

What industry is PharmaCyte Biotech in?

PharmaCyte Biotech's product category is Biotechnology Cellular Therapy. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingPharmaCyte Biotech Announces 1-for-19 Reverse Stock SplitPharmaCyte Biotech will implement a 1-for-19 reverse stock split effective November 12, 2026, with trading resuming November 13 under the same ticker. The split reduces outstanding shares from about 10.76 million to 566,087, aiming to restore Nasdaq's minimum bid price requirement. Holders will receive cash based on the split-adjusted closing price.Seeking AlphaPharmaCyte Biotech approves 1-for-19 reverse stock split for Nasdaq compliance (PMCB:NASDAQ)PharmaCyte Biotech approved a 1-for-19 reverse stock split effective November 12, 2026, reducing outstanding shares from about 10.75 million to 566,087. The split aims to raise the per-share price to regain Nasdaq's minimum bid price requirement.YahooPharmaCyte Biotech, Inc. Announces Reverse Stock SplitPharmaCyte Biotech's board approved a 1-for-19 reverse stock split, effective Nov 12, 2026, with trading on Nov 13, 2026. The split reduces outstanding shares from about 10.76 million to 566,087, aiming to regain Nasdaq listing compliance. Fractional shares will be paid in cash.American Banking and Market NewsPharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Down 2% – Here’s WhyPharmaCyte Biotech's stock fell 2% during mid-day trading on Friday, trading as low as $0.3865 and last at $0.3974. Volume surged 2,325% to 214,131 shares, up from an average of 8,831. The company, focused on pancreatic cancer therapies, has no approved commercial products.Ticker ReportPharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Down 2% – Should You Sell?PharmaCyte Biotech's stock fell 2% on Friday, trading as low as $0.3865 and closing at $0.3974. The company, a development-stage biotech focused on pancreatic cancer therapies, has not marketed an approved commercial product.Ticker ReportPharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Up 8.9% – What’s Next?PharmaCyte Biotech shares rose 8.9% to $0.4162 on Friday, with volume up 38,150%. The company develops Cell-in-a-Box cellular therapies for cancer and diabetes, with a lead trial combining the platform with ifosfamide for pancreatic cancer.Ticker ReportPharmaCyte Biotech (OTCMKTS:PMCBD) Shares Down 0.1% – Here’s What HappenedPharmaCyte Biotech Inc. shares fell 0.1% on Friday, trading as low as $0.5310 and closing at $0.5402, with about 57,214 shares exchanged, up 548% from the 8,831-share average session volume. The stock sits below its 50-day and 200-day moving averages at $0.64 and $0.69. The company is in clinical trials for pancreatic cancer combining its Cell-in-a-Box platform with ifosfamide.PharmacytePharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors :: PharmaCyte Biotech, Inc. (PMCB)PharmaCyte Biotech announced a $7 million financing with existing investors, selling 7,000 shares of Series C convertible preferred stock at $1,000 each. The securities convert into 7 million common shares and include warrants exercisable at $1.00 per share. The private placement is expected to close on August 19, 2025.AInvestPharmaCyte Biotech Boosts Stake in TNF Pharmaceuticals Amid Groundbreaking Computing Platform PartnershipPharmaCyte Biotech increased its stake in TNF Pharmaceuticals by $3 million to support TNF's license of LightSolver's light-based computing accelerator. TNF also entered a $7 million private placement for commercialization. The technology aims to cut energy costs by up to 90% in cryptocurrency applications.BioSpacePharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing InvestorsPharmaCyte Biotech announced a $7 million financing with existing investors, selling 7,000 shares of Series C preferred stock convertible into 7 million common shares and warrants. The private placement is expected to close on August 19, 2025, and the company will file an SEC registration statement for resale.